Raoul <span>R.</span> Salup, MD
Image Place holder

Raoul R. Salup, MD



    • Cancer Epidemiology Program

Education & Training

    • University of Pittsburgh, Resident - Urology
    • Phillips-Universitat Marbug, West Germany, MD - Medicine
    • City Hospital of Wiesbaden, West Germany, Assistant Resident - General Surgery
    • Johns Hopkins Hospital, Assistant Resident - Urology
    • NCI, Frederick Cancer Research Facility, Research Fellow - Biologic Therapeutics

Prostate cancer


  • Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget. 2017 Jun. Pubmedid: 28678746.
  • Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct;7(43):70794-70802. Pubmedid: 28053292. Pmcid: PMC5340117.
  • Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct;8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
  • Salup RR. Editorial comment. Urology. 2013 Apr;81(4):812. Pubmedid: 23414687.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar;33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Mar;2011(S3). Pubmedid: 22422102. Pmcid: PMC3300067.
  • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan;2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
  • Jim HS, Small BJ, Patterson S, Salup R, Jacobsen PB. Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. Support Care Cancer. 2010 Jan;18(1):21-27. Pubmedid: 19343369. Pmcid: PMC4090933.
  • Ulloa EW, Salup R, Patterson SG, Jacobsen PB. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer. Psychooncology. 2009 Jun;18(6):598-605. Pubmedid: 18942660.
  • Davila H, Mamcarz M, Nadelhaft I, Salup R, Lockhart J, Carrion R. Visualization of the neurovascular bundles and major pelvic ganglion with fluorescent tracers after penile injection in the rat. Bju Int. 2008 Apr;101(8):1048-1051. Pubmedid: 18070171.
  • Davila H, Weber T, Burday D, Thurman S, Carrion R, Salup R, Lockhart J. Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function. BJU Int. 2007 Nov;100(5):1026-1029. Pubmedid: 17868423.
  • Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007;59(2):163-168. Pubmedid: 18001210. Pmcid: PMC2435485.
  • Kumar NBB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer. 2007;59(2):169-175. Pubmedid: 18001211. Pmcid: PMC2442460.
  • Kumar N, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May;59(2):141-147. Pubmedid: 15042614.
  • Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, Gabrilovich D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol. 2004 Jan;172(1):464-474. Pubmedid: 14688356.
  • Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 2003 Dec;9(17):6523-6533. Pubmedid: 14695157.
  • Ouban A, Dellis J, Salup R, Morgan M. Immunohistochemical expression of Mdm2 and p53 in penile verrucous carcinoma. Ann Clin Lab Sci. 2003;33(1):101-106. Pubmedid: 12661905.
  • Bhattachary R, Bukkapatnam R, Prawoko I, Soto J, Morgan M, Salup R. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats. Int Immunopharmacol. 2002 May;2(6):783-796. Pubmedid: 12095169.
  • Morgan M, Stevens G, Tannenbaum M, Salup R. Expression of the caveolins in dermal vascular tumors. J Cutan Pathol. 2001;28(1):24-28. Pubmedid: 11168748.
  • Pirtskhalaishvili G, Shurin G, Esche C, Cai Q, Salup R, Bykovskaia S, LOtze M, Shurin M. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Brit J Cancer. 2000 Aug;83(4):506-513. Pubmedid: 10945499. Pmcid: PMC2374651.
  • Konety B, Metro M, Melhem M, Salup R. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract. Urol Int. 1999;62(1):26-30. Pubmedid: 10436427.
  • Lyne J, Melhem M, Finley G, Wen D, Liu N, Deng D, Salup R. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biological effects on prostate cancer cells in vitro. Can J Scient Amer. 1997;3:21-29. Pubmedid: 9072304.
  • Konety B, Singh J, Lyne J, Salup R. Leiomyosarcoma with osteoclast-like giant cells of the spermatic cord. Urol Int. 1996;56:259-262. Pubmedid: 8776828.
  • Salup RR, Sicker DC, Ballou BT, Flack CE, Wolmark N, Hakala TR. Improved lymphocyte cytotoxicity against murine renal cell carcinoma. J Urol. 1992 Feb;147(2):491-495. Pubmedid: 1732630.
  • Salup RR, Sicker DC, Wolmark N, Herberman RB, Hakala TR. Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin 2. J Urol. 1992 Apr;147(4):1120-1123. Pubmedid: 1552607.
  • Salup RR, Back TC, Wiltrout RH. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. J Immunol. 1987 Jan;138(2):641-647. Pubmedid: 3491854.
  • Salup RR, Wiltrout RH. Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease. Cancer Immunol Immun. 1986;22(1):31-36. Pubmedid: 3486715.
  • Salup RR, Herberman RB, Wiltrout RH. Role of natural killer activity in development of spontaneous metastases in murine renal cancer. J Urol. 1985 Dec;134(6):1236-1241. Pubmedid: 4057425.
  • Salup RR, Herberman RB, Chirigos MA, Back T, Wiltrout RH. Therapy of peritoneal murine cancer with biological response modifiers. J Immunopharmacol. 1985;7(4):417-436. Pubmedid: 3878855.
  • Morgan BE, Salup R, Morgan MB. Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder. Urol Oncol. 7(2):67-72. Pubmedid: 12474525.